Singapore, Aug. 27 -- Cytrellis Biosystems, Inc., a medical aesthetics company bridging the gap in skin health and restoration, has announced the commercial launch of ellacor(R) with Micro-Coring Technology in Australia following regulatory approval from Australia's Therapeutic Goods Administration.

The approval marks a significant international milestone for Cytrellis and ellacor(R) through exclusive distributor Device Consulting. Physicians across Australia will now have access to the company's groundbreaking Micro-Coring Technology - a first-of-its-kind approach that treats skin laxity and improves skin quality by removing micro-cores of skin without surgery.

Originally developed to address moderate to severe wrinkles and remove exce...